Latest News and Press Releases

VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development, manufacturing corporation specializing in...

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...

Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoidBolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential...

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...

VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...

Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development...

Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on...

Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...

Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...